Claire Thomas
Family Medicine · Richmond, VANPI 1952746406
Payments from drug & device makers
Across 150 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$474
- Amarin Pharma, Inc.$361
- Novo Nordisk$227
- GSK$209
- Amgen$201
- Lilly USA, LLC$186
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,682100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $474 |
| Amarin Pharma, Inc. | 19 | $361 |
| Novo Nordisk | 16 | $227 |
| GSK | 9 | $209 |
| Amgen(2 entities) | 13 | $201 |
| Lilly USA, LLC | 11 | $186 |
| AstraZeneca | 6 | $124 |
| Pfizer | 9 | $123 |
| Johnson & Johnson | 9 | $116 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Irhythm Technologies, Inc. | 1 | $94 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $42 |
| Medtronic | 2 | $33 |
| Merck | 2 | $32 |
| Novartis | 2 | $27 |
| Shire North American Group Inc | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Upsher-smith Laboratories LLC | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Concordia Pharmaceuticals Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$2,682 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $13,102 |
| JanuviaSitagliptin Phosphate | 13 | $8,336 |
| Atorvastatin Calcium | 52 | $494 |
| Metoprolol Succinate | 27 | $320 |
| Losartan Potassium | 28 | $274 |
| Levothyroxine Sodium | 26 | $258 |
| Rosuvastatin Calcium | 55 | $209 |
| Simvastatin | 14 | $131 |
| Amlodipine Besylate | 24 | $113 |
| Metformin Hcl ErMetformin Hcl | 24 | $101 |
| Hydrochlorothiazide | 15 | $54 |
| Lisinopril | 13 | $48 |
| Irbesartan | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $17 | $13,10212 claims |
| MerckJanuvia | $32 | $8,33613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Richmond
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Banks TurnerRichmond$74K
- James FosterRichmond$27K
- George MaughanRichmond$21K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.